(855) 475-4636

(855-4-SLIMDN)

10229 N. Scottsdale Rd Amici suite B. , Scottsdale AZ 85253

Research and Downloads

All of the latest news, studies and research in the weight loss and regenerative medicine.

Oprah Winfrey reveals she uses weight-loss drugs, calls it a ‘gift’

Oprah Winfrey revealed that she uses a weight-loss drug as part of her health routine. After calling use of medication “the easy way out,” she now says it’s “like a gift.” NBC’s Emilie Ikeda reports and Dr. Roshini Raj joins TODAY on how the Winfrey is helping lift the shame of treating obesity.

Watch on YouTube Here.

Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study

People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday. That translated into an average 50-pound loss for people who took Zepbound, while Wegovy users lost 33 pounds.

Download the Article Here.

Oprah Winfrey opens upabout exiting Weight Watchers after using weight-loss drug.

In a March 2024 ABC special, Oprah Winfrey delved into the rising use of weight loss drugs like Ozempic, discussing their benefits and potential risks. She shared her personal experiences with weight management and engaged with medical experts to provide a comprehensive overview of these medications. The program aimed to inform viewers about the complexities of obesity treatment and the implications of using pharmaceutical aids for weight loss.

Find the Full Article Here.

How Do GLP-1 Agonists Help with Inflammation?

GLP-1 agonists, known for managing blood sugar and body weight, also exhibit anti-inflammatory properties. Recent studies suggest these medications may reduce systemic inflammation through mechanisms involving the brain. Research published in Cell Metabolism indicates that GLP-1 agonists can influence brain signaling pathways, leading to suppressed inflammation in other body regions. Additionally, findings in Kidney International reveal that liraglutide, a GLP-1 agonist, can decrease inflammation associated with kidney disease. These insights enhance our understanding of the broader therapeutic potential of GLP-1 agonists beyond diabetes and obesity treatment.

Find the Full Article Here.

Vtiality Slim Clinic

Book an Appointment

Connect

Location & Hours

10229 N. Scottsdale Rd Amici suite B. , Scottsdale AZ 85253

Hours of Operation

Tuesday - Saturday 10am to 6pm

Sunday & Monday - CLOSED

Novo Nordisk’s Wegovy wins FDA approval for cutting heart disease risks

In March 2024, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk's weight-loss drug, Wegovy, for reducing the risk of major adverse cardiovascular events—such as heart attack, stroke, and cardiovascular death—in adults with obesity or overweight and established cardiovascular disease. Novo Nordisk US This decision was based on the SELECT trial, which involved over 17,600 participants and demonstrated a 20% reduction in such events for those treated with Wegovy compared to a placebo. Novo Nordisk US The approval is expected to enhance insurance coverage for Wegovy, potentially improving accessibility for patients at risk of heart disease.

Read the Full Article Here.

DOWNLOAD - A Weight-Loss Breakthrough That Finally Works

Looking for a safe and effective solution to weight loss? A new FDA-approved medication, featured in Medical Times Today, is transforming lives by helping patients achieve long-term weight loss without the need for drastic diets or surgery. Offered at Doctor's Medical Weight Loss Clinic, this once-weekly medication works naturally with the body to reduce appetite, slow digestion, and lower the body's weight "set point." Backed by clinical trials showing up to 30% body weight loss and endorsed by experts, this breakthrough is a game-changer in obesity treatment. Explore how this innovative approach is helping patients regain their health, confidence, and vitality.

Download the Article Here.

Could A Diabetes Drug Be A Game Changer for Weight Loss

In the first nationally aired feature about GLP-1, Dr. Oz sits down with Dr. Robert Kushner, a leading obesity researcher from Northwestern University, to discuss the results of a 68-week clinical trial. Learn how Semaglutide helped participants lose an average of 15% of their body weight, translating to around 33 pounds. Hear the inspiring story of a woman who lost 40 pounds during the trial and explore this drug's potential to change lives.